Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
about
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesityIs GLP-1 a hormone: Whether and When?The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesityThe L-Cell in Nutritional Sensing and the Regulation of AppetiteGLP-1, the gut-brain, and brain-periphery axesDPP-4 inhibition and islet functionThe physiological role of the brain GLP-1 system in stressGlucagon-like peptide 1 interacts with ghrelin and leptin to regulate glucose metabolism and food intake through vagal afferent neuron signalingEmerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetesLiraglutide and obesity: a review of the data so far.An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics.Combination treatment of db/db mice with exendin-4 and gastrin preserves β-cell mass by stimulating β-cell growth and differentiation.Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction.Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats.Inhibition of dipeptidyl peptidase-4: The mechanisms of action and clinical use of vildagliptin for the management of type 2 diabetes.Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes.Preproglucagon neurons project widely to autonomic control areas in the mouse brain.Inhibition of dipeptidyl peptidase-IV enzyme activity protects against myocardial ischemia-reperfusion injury in rats.What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tractPeripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.Gut microbiota, nutrient sensing and energy balance.Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake.β-Cell Sensitivity to GLP-1 in Healthy Humans Is Variable and Proportional to Insulin Sensitivity.Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Is endogenous GLP-1 the only important enhancer of glucose-induced insulin secretion in type 2 diabetes?GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test.Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4Newer therapeutic options for children with diabetes mellitus: theoretical and practical considerations.Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.Herbal therapies for type 2 diabetes mellitus: chemistry, biology, and potential application of selected plants and compoundsEnteroendocrine cells: a review of their role in brain-gut communicationResistin regulates pituitary lipid metabolism and inflammation in vivo and in vitro.Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?Nucleus accumbens GLP-1 receptors influence meal size and palatability.An Innate Disposition for a Healthier Gut: GLP-1R Signaling in Intestinal Epithelial Lymphocytes.
P2860
Q24653673-AD3BA210-169F-43B8-A61E-882A596212FAQ26749196-3821B1A0-8BD2-4E4E-98F4-E39AFCD2061DQ26765609-6C222866-A9F9-4E82-9765-A9B49C6B05F8Q26799942-801DC397-49BD-43C1-B4A9-46D5BAA42CBDQ27000749-C8F6432F-10D0-4088-9D83-9E5F1691447FQ27028127-57788F47-7D75-4991-B5C4-B768F1C99F43Q28077787-92782B65-60D0-4778-9025-9E9C2BD859D5Q28084873-1614137B-331F-4937-B138-79D857044802Q28762629-18CC0B74-C78A-4191-9B10-5F470C400525Q30924982-795FE395-A7AE-4190-9DF0-3FE1D95D7BF3Q31131623-AFE9372F-DB09-4360-80DC-48B6AD76EB68Q33609727-E735CBFC-50B8-4B66-86DE-C11ADBD44DD3Q33973990-A628544A-CBE7-4E7D-A17E-D4CA88EE2419Q34219918-BA1A14C9-40AF-43E3-86D6-62B2BEEBAAF9Q34265490-3011F063-3DF8-4EC2-822F-97EC8B3B1E41Q34508051-2428050F-B4E2-47DD-9DEE-3ED045CE8858Q34614609-0A75A27B-6B76-43DF-A975-28B313939C5FQ34620636-709C72F5-01E6-4A98-A142-1776D281E306Q34620693-F13D7543-A2BA-46BA-9BFE-A1A00CCA4578Q34981134-67DFFD7C-44FA-4267-874C-3A501CC23800Q34993368-03352047-A5C9-4D29-BA52-7C4B97B1212EQ35110830-6C7A731E-BC0E-4EBA-9E9A-2258072780DCQ35110843-0BA41261-AE87-4244-BFED-734BB5C9FFD3Q35243151-73FBB3AD-090A-46DE-8272-7FD81586C980Q35601526-A622BC74-317A-4BC8-8636-E106F63B4DD0Q35680897-30B0F9C5-987D-48CF-A08B-B62834916E0AQ35893496-722B10A8-C4FB-416E-94D9-BA78482EA8C7Q35906506-3823B481-3847-4015-A8CE-81451216E03EQ36182510-DBE24D12-D60B-4484-8CCF-8F95E2E6D43CQ36335898-0D5630E8-EF0B-43D5-88A8-B88F6DDEFCFBQ36339659-F5894C84-BF62-4572-B741-80044CA40303Q36439654-B26D31D5-477F-4B4D-8B9B-4917CC2646DCQ36455865-74E797F1-1640-4D23-B6BA-291DDE2ACC22Q36735761-2ADD8AFA-44D5-464D-89A3-D19C8E91C289Q36801780-453DFBC8-0134-41AD-B180-9E318A05CCF7Q36828610-6D30FEF0-C1DE-41A9-B8C0-95801FBC5EBDQ36844999-B9E943B2-8472-45DE-BE0C-E416E3579B97Q36860616-B76D8E90-1AEE-4BCE-A1B6-C328ACB8078CQ36923698-137AFC19-F269-46C9-B607-30704E1F44AAQ36926355-73377A5E-DB48-4D3E-8824-8F06D108E80D
P2860
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@en
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@nl
type
label
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@en
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@nl
prefLabel
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@en
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@nl
P1433
P1476
Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
@en
P2093
C F Deacon
P2888
P304
P356
10.1007/S00125-005-1705-7
P577
2005-03-10T00:00:00Z